IRAK3 and cancer: Induction of IRAK3 expression is required for development of ‘endotoxin tolerance’ [6,17] and ‘cancer-induced monocyte tolerance’ [32], and tumors with high IRAK3 expression show enriched anti-inflammatory pathways and a worse clinical response to immune checkpoint blockade therapy [33].